Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 6/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19066055 | 1.00 | HSD17B10 (0.39) | HSD17B10HDAC8CHRM2CHRM1CHRM3 | |
| SCHEMBL20446514 | 1.00 | HSD17B10 (0.39) | HSD17B10HDAC8CHRM2CHRM1CHRM3 | |
| SCHEMBL3661716 | 0.86 | PTPN1 (0.38) | HSD17B10HDAC8CHRM2CHRM1CHRM3 | |
| SCHEMBL20487628 | 0.86 | PTPN1 (0.38) | HSD17B10HDAC8CHRM2CHRM1CHRM3 | |
| SCHEMBL3661719 | 0.86 | PTPN1 (0.38) | HSD17B10HDAC8CHRM2CHRM1CHRM3 | |
| SCHEMBL31078014 | 0.86 | HSD17B10 (0.42) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL1848946 | 0.81 | HSD17B10 (0.41) | HSD17B10HDAC8CHRM2CHRM1CHRM3 | |
| SCHEMBL19388647 | 0.81 | HSD17B10 (0.41) | HSD17B10HDAC8CHRM2CHRM1CHRM3 | |
| SCHEMBL193268 | 0.81 | HSD17B10 (0.41) | HSD17B10HDAC8CHRM2CHRM1CHRM3 | |
| SCHEMBL19083907 | 0.81 | ATM (0.33) | HSD17B10ATMCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2922535-B1 | THROMBIN INHIBITORS | MERCK SHARP & DOHME (US) | 2021-11-10 | — | — | EP | disclosed |
| US-9714231-B2 | Pyrrolidine GPR40 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-25 | — | — | US | disclosed |
| EP-3166939-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | Genentech, Inc. (US) | 2017-05-17 | — | — | EP | disclosed |
| EP-2925741-B1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2016-10-26 | — | — | EP | disclosed |
| US-9469608-B2 | Thrombin inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-10-18 | — | — | US | disclosed |
| US-20160280680-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-09-29 | — | — | US | disclosed |
| WO-2016007534-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-01-14 | — | — | WO | disclosed |
| US-20150315141-A1 | Thrombin Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-11-05 | — | — | US | disclosed |
| EP-2925741-A1 | PYRROLIDINE GPR40 MODULATORS | Bristol-Myers Squibb Company (US) | 2015-10-07 | — | — | EP | disclosed |
| WO-2014078609-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315141-A1 | Thrombin Inhibitors | F3, F2, F9 | HSD17B10 1410/4885HDAC8 245/4885CHRM2 146/4885 |
| US-20160280680-A1 | PYRROLIDINE GPR40 MODULATORS | GPR55, GPR65, GPR27 | HSD17B10 1281/4885HDAC8 1690/4885CHRM2 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.